Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.
Cdon, a cell surface protein, mediates oligodendrocyte differentiation and myelination.
Application of q-Space Diffusion MRI for the Visualization of White Matter.
Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis.
Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI.
Depression and sleep disturbances in patients with multiple sclerosis and correlation with associated fatigue.
Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis.
Longitudinal monitoring of metabolic alterations in cuprizone mouse model of multiple sclerosis using 1H-magnetic resonance spectroscopy.
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
Use of botulinum toxin for genitourinary conditions: What is the evidence?
Proton detection for signal enhancement in solid-state NMR experiments on mobile species in membrane proteins.
Relapsing multiple sclerosis patients can look to second oral agent.
Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis.
Pain-related mood influences pain perception differently in fibromyalgia and multiple sclerosis.
Gender and autoimmune comorbidity in multiple sclerosis.
Regulation: The FDA is overcautious on consumer genomics.
Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012.
Stabilometric assessment of context dependent balance recovery in persons with multiple sclerosis: a randomized controlled study.
Self-report versus performance measure in gauging level of function with multiple sclerosis.
Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathways.
Political notebook.
Identification of Dominant Human Aquaporin 4 T-Cell Epitopes: Observations in Neuromyelitis Optica With Implications for Other Autoimmune DisordershAQP4 T-Cell Epitopes.
Diffusion Tensor Analysis of Pediatric Multiple Sclerosis and Clinically Isolated Syndromes.
Naturally Occurring Antibodies as Therapeutics for Neurologic Disease : Can Human Monoclonal IgMs Replace the Limited Resource IVIG?
Propentofylline treatment on open field behavior in rats with focal ethidium bromide-induced demyelination in the ventral surface of the brainstem.
Pages
« first
‹ previous
…
442
443
444
445
446
447
448
449
450
…
next ›
last »